Patient's question:
Doctor: Our son is almost 50 days old, but the jaundice has not subsided yet. We have taken him to the hospital twice to get vaccinations, but both times he was rejected because of the jaundice. At home, we have given him "Three Yellow Decoction," exposed him to sunlight, had him drink more water, and reused glucose, but none of these have been effective. We are very worried! What should we do? Please help us.Doctor's answer:
Okay, here is the translation of the provided text into English, following your instructions regarding line breaks and translation of Chinese content.I. Clinical Characteristics of Neonatal Jaundice
When serum bilirubin levels in adults exceed 34 μmol/L, jaundice appears in the skin and mucous membranes. However, newborns generally have a higher tolerance due to a greater number of red blood cells in their capillaries, differences in the transparency of skin and mucous membranes compared to adults, or weaker binding capacity of skin to bilirubin. Therefore, jaundice typically becomes apparent only when blood bilirubin levels exceed 68 μmol/L.
The sequence of jaundice appearance in adults is usually first observed in the sclera and oral mucosa, followed later by the skin. However, in newborns, the tighter connective tissue and fewer lymphatic spaces in the conjunctiva hinder the deposition of bilirubin pigment, resulting in scleral jaundice appearing after skin jaundice.
II. Physiological Jaundice in Newborns
Before birth, during the fetal period, newborns have immature liver function with insufficient capacity for both the conjugation and excretion of bilirubin. Their primary metabolism relies on the mother's liver. Consequently, under normal conditions, non-conjugated bilirubin in umbilical cord blood is only 17-50 μmol/L. The amount of bilirubin converted by the fetus's own liver is small, so even with congenital biliary atresia, neither the fetus nor the newborn exhibits jaundice. However, some non-conjugated bilirubin from the fetus is still converted to conjugated bilirubin by its own liver and excreted via the intestine, which gives fetal meconium its brown color. When hemolysis occurs in the fetus, the large amount of non-conjugated bilirubin produced cannot be fully transferred across the placenta to the mother due to the limited conversion capacity of the fetal liver. This results in fetal jaundice and yellowing of the amniotic fluid.
After birth, the newborn loses the placental route for bilirubin excretion, and the liver's ability to metabolize bilirubin is not yet fully mature. For example: ① Z-protein within hepatocytes is fully developed during the fetal period, while Y-protein, which primarily binds non-conjugated bilirubin, is present in very low amounts at birth and is nearly absent, requiring 2-3 weeks to reach maturity; ② Glucuronosyltransferase activity in hepatocytes is only 10% of that in adults at birth and gradually increases with age, approaching adult levels around 2 weeks after birth; ③ UDP-glucuronate dehydrogenase activity is also low, and the content of UDP-glucuronic acid is scarce, both of which affect bilirubin conjugation. Additionally, factors contributing to this include: ① High bilirubin load. After birth, newborns establish pulmonary respiration, and blood partial pressure of oxygen rapidly exceeds that in the fetal environment. The high red blood cell count, combined with their short lifespan (70-100 days), leads to excessive bilirubin production. Furthermore, the source of shunt bilirubin is also greater than in adults. Thus, newborns generate 8.5 mg/kg of bilirubin daily, compared to only 3.8 mg/kg in adults. ② Increased enterohepatic circulation. In newborns, the normal gut flora has not yet been established. Consequently, conjugated bilirubin entering the intestine cannot be reduced to stercobilinogen as it can in older children. Instead, the higher activity of β-glucuronidase in the newborn gut hydrolyzes conjugated bilirubin into non-conjugated bilirubin and glucuronic acid, with the former being absorbed back into the liver from the intestine. This absorption is increased when meconium delayed passage occurs.
Due to these characteristics, 90% of newborns have blood bilirubin levels exceeding 34 μmol/L within the first week of life, and 60% of full-term newborns and 80% of preterm infants develop jaundice during this period. Umbilical cord blood bilirubin levels at birth typically range from 17-51 μmol/L and increase within the first 24 hours but do not exceed 85 μmol/L. Therefore, jaundice usually appears on the second or third day after birth. Bilirubin levels peak between 2-4 days after birth, generally ranging from 85-102 μmol/L, and then gradually decline, falling below 34 μmol/L by days 5-7, after which jaundice resolves. Preterm infants, with less mature liver development, exhibit deeper jaundice, with peaks occurring between days 4-7 and peak bilirubin levels reaching 136-204 μmol/L. Jaundice resolves later in these infants, although it is rarely seen after 10 days and occasionally persists for 1-2 months. Since this type of jaundice is a normal physiological feature of newborns and does not cause any pathological harm to the organism, it is termed physiological jaundice. Physiological jaundice can become more severe under certain conditions, such as chronic fetal hypoxia in utero leading to fetal erythrocytosis due to blood group incompatibility, or neonatal head trauma resulting in intracranial hematoma, both of which increase the source of bilirubin. Conditions like asphyxia, hunger, infection, hypothermia, or acidosis in newborns can impair the liver's ability to metabolize bilirubin, thereby worsening jaundice.
The diagnosis of physiological jaundice requires careful exclusion of various pathological jaundices. Pathological jaundice should be suspected in the following situations: ① Jaundice appears within the first 24-36 hours after birth; ② Daily increase in bilirubin levels exceeds 85 μmol/L; ③ Bilirubin levels in full-term newborns (especially those without risk factors) exceed 204 μmol/L, or in preterm infants exceed 171-239 μmol/L; ④ Jaundice persists for more than 10-14 days; ⑤ Jaundice reappears or progressively worsens after initially resolving; ⑥ Conjugated bilirubin levels > 34 μmol/L or bilirubin is detected in the urine; ⑦ Liver enlargement or/and increased liver stiffness; ⑧ Other signs such as pallor, vomiting, poor appetite, or hypothermia.
III. Etiology and Clinical Manifestations of Infant Jaundice
Infant jaundice is common and can be classified according to its underlying mechanism into: ① Pre-hepatocytic jaundice; ② Hepatocytic jaundice, which can be further subdivided into microvesicular jaundice and mixed jaundice; and ③ Post-hepatocytic jaundice. Several common diseases are associated with each type of jaundice. The etiology and clinical manifestations of these diseases are described below:
(1) Pre-hepatocytic Jaundice
Pre-hepatocytic jaundice is also known as hemolytic jaundice. In infancy, it can result from various causes such as infections, physical and chemical factors, antigen-antibody reactions, and hypersplenism, leading to massive red blood cell destruction and the production of excessive non-conjugated bilirubin, which exceeds the infant liver's conversion capacity, thereby causing jaundice. The more common diseases include:
1. Hemolytic Disease of the Newborn (HDN), also known as Erythroblastosis Fetalis, is an isoimmunization hemolytic disease caused by blood group incompatibility between the mother and fetus. Maternal antibodies against fetal red blood cells cross the placenta into the fetal circulation, causing significant fetal red blood cell destruction. Although over 60 red blood cell antigens have been identified as capable of inducing antibody responses, clinically, the most common forms are HDN resulting from Rh D antigen incompatibility and ABO blood group incompatibility. In China, ABO incompatibility is more common, while Rh incompatibility is less frequent. In ABO incompatibility, the newborn is typically type A (especially A1, which has a stronger antigenicity than A2), and the mother is type O. The newborn's A-type red blood cells enter the mother's circulation during the fetal period, prompting the mother to produce immune antibodies, which then cross the placenta to cause fetal hemolysis. Since A and B antigens or antibodies are widely present in nature, O-type women may have pre-existing corresponding antibodies (IgG 7S fragment) even without pregnancy, leading to ABO incompatibility manifesting in the firstborn infant. Jaundice appears immediately at birth and progressively deepens, with severe cases accompanied by edema. Due to extensive hemolysis, excessive bilirubin is produced, which the newborn liver cannot adequately conjugate, resulting in hyperbilirubinemia. This unconjugated bilirubin is lipid-soluble and can cross the blood-brain barrier into the newborn's brain. High levels (reaching 306-340 μmol/L) pose a risk of kernicterus. Mild cases may present with drowsiness, vomiting, and hypotonia; severe cases may manifest as convulsions and opisthotonos. This condition can be diagnosed by examining the blood types of both the mother and fetus and detecting antibodies in the newborn's blood that are compatible with its own blood type (e.g., anti-A antibodies). Mild cases can be treated with enzyme inducers like phenobarbital, intravenous administration of traditional Chinese medicine Yin-Zhi-Huang (containing Bupleurum, Gentian, and Scutellaria), intravenous albumin, and phototherapy; severe cases may require exchange transfusion.
2. Glucose-6-Phosphate Dehydrogenase (G-6-PD) Deficiency is an X-linked incomplete dominant genetic disorder. It is more prevalent in regions like Guangdong, Guangxi, Sichuan, and Fujian in China. Due to the lack of G-6-PD in red blood cells, the production of reduced NADPH is insufficient, leading to decreased levels of reduced glutathione (GSH) in red blood cells. The sulfhydryl groups in membrane proteins, hemoglobin, and cytoplasmic enzymes within red blood cells are oxidatively inactivated, and the conversion of methemoglobin to oxyhemoglobin is reduced, making red blood cells more susceptible to hemolysis. Some patients may exhibit symptoms during the neonatal period, referred to as Neonatal G-6-PD Deficiency, with jaundice appearing within 48 hours of birth and progressing rapidly. Severe cases may develop kernicterus within one week or even result in death. This form often occurs without a clear trigger, potentially related to lower GSH activity and blood glucose levels in newborn red blood cells and the liver. Other infants may develop hemolysis after taking oxidant drugs such as acetylsalicylic acid (ASA), furazolidone, or furazolidone, or after consuming breast milk from mothers who have recently eaten fava beans or consuming fava beans and their products. The diagnosis of this condition primarily relies on methemoglobin reduction tests and G-6-PD activity assays.
(2) Hepatocytic Jaundice
Infant hepatocytic jaundice, similar to adults, can be classified according to the mechanism of jaundice onset into: ① Microsomal pre-hepatocytic jaundice (primarily due to impaired uptake of unconjugated bilirubin by hepatocytes, as in Gilbert syndrome); ② Microsomal jaundice (due to insufficient glucuronosyltransferase activity); ③ Microsomal post-hepatocytic jaundice (impaired excretion of conjugated bilirubin from hepatocytes, as in Dubin-Johnson and Rotor syndromes); and ④ Mixed jaundice (widespread hepatocellular disease). Clinically, mixed jaundice is the most common.
1. Microsomal Jaundice
(1) Breast Milk Jaundice (Jaundice Associated with Breastfeeding): The etiology is unclear, and some infants may develop this due to the presence of glucuronidase in breast milk, which increases enterohepatic circulation of bilirubin. The incidence is approximately 2%. Affected infants show a significant increase in unconjugated bilirubin in their blood within 7 days of birth, peaking at 2-3 weeks, and then gradually declining, maintaining a low level for about 3-10 weeks. Jaundice resolves rapidly within 2-4 days after stopping breastfeeding and disappears completely within 6-9 days. If breastfeeding is resumed, jaundice may reappear, but usually to a lesser degree. As the prognosis is generally good, discontinuing breastfeeding is sufficient without the need for other specific treatments.
(2) Hereditary Glucuronosyltransferase Deficiency (Crigler-Najjar Syndrome): This condition has two types, both inherited as autosomal traits. Type I (the severe form) is characterized by a complete lack of glucuronosyltransferase, with severe jaundice appearing within the first 3 days of life. Bilirubin levels can reach as high as 427-598 μmol/L within the first month of life, and without prompt treatment, kernicterus often leads to death within the first week. This condition does not respond to phenobarbital treatment. Phototherapy may be used in childhood, but the skin may become hard later in life, making treatment difficult. There have been reports of successful treatment with liver transplantation. Type II (the mild form) involves partial or functional deficiency of glucuronosyltransferase in hepatocytes and can be treated with phenobarbital. Jaundice appears later in this type, ranging from the neonatal period to adulthood. Bilirubin levels are usually below 34 μmol/L.
2. Mixed Jaundice is essentially what is referred to as "narrow-sense hepatocytic jaundice." Due to extensive damage to hepatocytes, they cannot convert all unconjugated bilirubin in the blood to conjugated bilirubin. Additionally, liver cell swelling compresses the capillaries and intrahepatic bile canaliculi, impairing the excretion of conjugated bilirubin from the liver and causing it to reflux into the bloodstream. This results in mixed jaundice, which is more common in hepatocellular diseases during infancy.
(3) Post-hepatocytic Jaundice
Infant post-hepatocytic jaundice, classified according to the anatomic site of onset, can include: ① Intrahepatic cholestasis syndromes; ② Congenital biliary cystadenoma; ③ Congenital extrahepatic biliary atresia; and ④ Upper intestinal obstructive hyperbilirubinemia.
1. Intrahepatic Cholestasis Syndromes refer to conditions where bile acid metabolism disorders, impaired bile secretion by hepatocytes, or abnormal intrahepatic bile duct development prevent the complete excretion of bile into the biliary system and intestinal lumen. Instead, bile accumulates within hepatocytes, capillaries, or intrahepatic bile ducts and refluxes into the bloodstream, leading to increased levels of both conjugated bilirubin and bile acids in the blood. Consequently, affected infants not only have jaundice but also experience skin itching stimulated by bile acids. Generally, there are no other signs of hepatocellular damage, so ALT levels are not elevated. However, in severe cases, biliary cirrhosis can develop. This syndrome includes: ① Benign recurrent cholestasis. This condition often has a familial history, with recurrent episodes of jaundice and itching preceded by prodromal symptoms such as anorexia and weakness 2-4 weeks before onset. Each episode lasts for 1-3 weeks and is followed by intervals of several weeks to years. Between episodes, the child is usually asymptomatic. 19% of patients develop symptoms before one year of age. ② North American Indian cholestasis. Found in Quebec, Canada, this is an autosomal recessive condition that typically manifests 3 months after birth. It is characterized by cholestasis, hepatosplenomegaly, and telangiectasia, and often leads to cirrhosis and death. ③ Aagenaes syndrome, also known as Norwegian cholestasis. This is an autosomal recessive condition characterized by jaundice appearing at birth or within the first week of life, with cholestasis persisting for many years, followed by multiple recurrences. Lower limb lymphedema may develop later in childhood. ④ Alagille syndrome, also known as hepatic artery developmental defect. This is an autosomal dominant condition with variable penetrance, typically manifesting within the first 3 months of life but sometimes as late as age 3. It gradually improves within 2 years but frequently recurs, often accompanied by hepatomegaly and xanthomas on the skin. Additional features commonly include atrial septal defect, pulmonary artery stenosis, deep-set eyes, prominent forehead, straight nose, and micrognathia. ⑤ Byler disease. Affects members of the Amish community, with early childhood onset of itching, rickets, and steatorrhea, followed by the development of jaundice. Associated features include hepatosplenomegaly, poor growth, and mental retardation. ⑥ Patients receiving long-term parenteral nutrition may also develop cholestasis, which is more common in preterm infants.
2. Upper Intestinal Obstructive Hyperbilirubinemia occurs in conditions like congenital duodenal atresia, upper small intestinal atresia, or annular pancreas. In these cases, conjugated bilirubin reaching the intestinal lumen cannot be excreted via the colon and is instead converted to unconjugated bilirubin by active β-glucuronidase in the intestinal lumen, which is then absorbed back into the bloodstream, causing hyperbilirubinemia. Additionally, some infants with idiopathic hypertrophic pyloric stenosis may also have jaundice, which can appear 2-3 days before projectile vomiting. Jaundice typically resolves only after surgical treatment. The exact mechanism of hyperbilirubinemia in this condition is unclear, but it has been suggested that it may result from insufficient caloric intake and glucuronosyltransferase deficiency in the infant, or from excessive serum gastrin levels inhibiting the activity of this enzyme.
3. Congenital Extrahepatic Biliary Atresia is a relatively common disease, typically presenting with jaundice during the neonatal period (earliest within the first few days after birth, latest after 2-3 weeks), accompanied by clinical signs such as acholic stools, and is more common in females. There are two main possible mechanisms for its occurrence: One is congenital malformation, where damage to bile duct and spleen development during the 25-40th day of embryonic development affects both organs, known as biliary atresia with splenic malformation syndrome, seen in 10% of cases. Alternatively, during the 11-13th week of embryonic development, the bile ducts may fail to develop in the correct sequence (, , and ), leading to developmental disorders or arrest and preventing the formation of a fully patent extrahepatic bile duct. The other mechanism is obstructive biliary disease, caused by infections like cytomegalovirus during the in utero or perinatal period, leading to inflammatory changes in the extrahepatic bile ducts, resulting in ductal obstruction, atrophy, or partial disappearance of the bile ducts. In cases where this latter factor is the cause, neonatal hepatitis (jaundice with yellow-brown stools) may first appear, followed later by the signs of biliary atresia. Therefore, some international researchers classify this condition into two types: ① Fetal-embryonic type, where jaundice appears very early, with no interval between physiological jaundice and pathological jaundice, accounting for 34% of 342 cases. ② Antenatal, perinatal, or postnatal type, where jaundice appears later, resulting in a few days to a few weeks of jaundice-free interval after physiological jaundice, accounting for 66% of cases. From the perspective of pathological anatomy, this condition can be divided into three basic types: Ⅰ Type choledochal atresia, where all or part of the common bile duct is absent despite the formation of hepatic ducts, leaving the extrahepatic bile ducts ending in a blind pouch, accounting for 5%-10% of cases and potentially amenable to surgical treatment. Ⅱ Type hepatic duct atresia, where most or all extrahepatic bile duct structures are absent, making surgical treatment impossible. Ⅲ Type hilar atresia, the most common type, accounting for approximately 85%, and also unsuitable for surgical treatment. Prolonged biliary atresia leads to the accumulation of bile in the liver, gradually resulting in biliary cirrhosis. Additionally, affected infants often have associated conditions such as malnutrition, anemia, and rickets. Except for some cases (like Types Ⅰ and Ⅱ where bile ducts still connect to the liver), most cases ultimately progress to liver failure and death. Liver transplantation can save the lives of affected infants and achieve satisfactory outcomes.
4. Congenital Biliary Cystadenoma results from congenital cystic dilation of the common bile duct, causing impaired bile flow and leading to obstructive jaundice. The causes include: ① Congenital anatomical abnormalities of the pancreas and biliary tract, where the common bile duct and pancreatic duct fail to separate normally during embryonic development. Consequently, pancreatic juice flows through a common pancreatico-biliary channel into the common bile duct, damaging the elastic fibers of the bile duct wall and causing it to lose tone, leading to dilation. ② Uneven proliferation of bile duct epithelium. That is, when epithelial cells within the primitive bile duct proliferate and transform into solid tissue, uneven development occurs between the upper and lower parts. Excessive proliferation at the distal end results in stenosis during cavitation and recanalization, while the proximal end becomes dilated, forming a cyst. ③ Viral infection of the bile duct epithelium leads to local destruction of the common bile duct, which may result in dilation later. Based on anatomical morphology, this condition is primarily divided into two types: ① Cystic dilation type, the most common type, accounting for approximately 93%. It can be spherical or fusiform, but most are spherical. The size of the cysts varies, ranging from small to holding 2-3 liters of fluid. ② Diverticular type, accounting for 6%. ③ Cystic prolapse of the common bile duct orifice, accounting for 2%. Additionally, associated conditions can include cystic dilation of intrahepatic bile ducts. This condition is also more common in females and symptoms typically appear around the age of 3, although it may sometimes begin to manifest within a few months after birth. Clinically, in addition to jaundice, symptoms may include abdominal masses and abdominal pain. However, only 20%-30% of cases exhibit all three symptoms simultaneously. Abdominal ultrasound is often diagnostic. Treatment is primarily surgical. Delayed diagnosis and treatment can lead to cholangitis and cirrhosis.